 Reuters UK |
Glaxo on the slide after trials setback for asthma drug
Evening Standard But clinical trials have not shown the new treatment to be better than GSK's flagship asthma drug Advair. "The results aren't a home run but look adequate for filing and approval," said pharma analyst Emmanuel Papadakis at Collins Stewart. … GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies … GSK to seek approval of Theravance lung drug For COPD, Glaxo intends to submit regulatory applications in the US and Europe … |
View full post on asthma – Google News